

Notice of Allowability	Application No.	Applicant(s)
	09/937,673 Examiner	REDOULES ET AL. Art Unit
	Devesh Khare	1623

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTO-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. This communication is responsive to 01/20/2004.
2. The allowed claim(s) is/are 16-19, 21, 22 and 24-33.
3. The drawings filed on _____ are accepted by the Examiner.
4. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All b) Some* c) None of the:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. PCT/FR0082.
 3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____


Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

5. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
6. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
 - (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 - 1) hereto or 2) to Paper No./Mail Date _____.
 - (b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. Notice of References Cited (PTO-892)
2. Notice of Draftsperson's Patent Drawing Review (PTO-948)
3. Information Disclosure Statements (PTO-1449 or PTO/SB/08),
Paper No./Mail Date _____
4. Examiner's Comment Regarding Requirement for Deposit
of Biological Material
5. Notice of Informal Patent Application (PTO-152)
6. Interview Summary (PTO-413),
Paper No./Mail Date 6-18-2004.
7. Examiner's Amendment/Comment
8. Examiner's Statement of Reasons for Allowance
9. Other _____

JAMES O. WILDER
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 2900

James O. Wilder

Applicant's remarks filed on 01/20/04 are acknowledged. The declaration by Dr. Daniel Redoules filed on 01/20/04 is acknowledged. Applicant's amendment sent by e-mail on 6/18/04 has been entered. Claims 16, 18, 19, 21, 24, 26 and 31-33 have been amended. Claims 1-15, 20 and 23 have been cancelled. The rejection of claims 16-19, 21, 22 and 24-33 under 35 U.S.C 103(a) based on Bollag et al. in view of von Deesen et al., has been overcome through applicants' amendment to the claims.

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given by Patrick Sage on 6/18/04.

1. In claim 31, line 1, the term "Claim 20" has been replaced by the term "Claim 16".
2. Claims 16, 18, 19, 21, 24, 26 and 31-33 have been amended (a clean sheet of the claims is attached)
3. Claims 1-15, 20 and 23 have been cancelled.

Claims 16-19, 21, 22 and 24-33 are currently pending in this application.

Claims 16-19, 21, 22 and 24-33 are allowed.


2. The following is an examiner's statement of reasons for allowance: The claims of the present invention are directed to a glucosyl complex of retinoic acid, wherein

glucose is attached to a linear, branched or cyclized hydrocarbon based spacer group of aliphatic or aromatic nature and a retinoic acid molecule is linked to the spacer via a carboxylate function and its pharmaceutical composition which is a bioprecursor of at least one retinoic active principle, intended for percutaneous application; and a process for preparing the said complex, is not taught or fairly suggested by the prior art of the record.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

3. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703)308-1235.

Devesh Khare, Ph.D., J.D.
Art Unit 1623
June 21, 2004



JAMES O. WILSON
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600